

1 **Novel Domain V mutation in *cfr*-positive clinical *Staphylococcus haemolyticus***
2 **isolates causing linezolid resistance in Egyptian ICU patients**

3

4 Saber Maghraby¹, Mohamed Ez El-Din Dawoud¹, Mohamed Eweis¹, Abdullah El-
5 nagish^{2*}, Doaa Ghaith³

6 ¹ Department of Botany and Microbiology, Faculty of Science, Cairo University,
7 Cairo, Egypt

8 ² Department of Botany and Microbiology, Faculty of Science, Sohag University,
9 82524 Sohag, Egypt

10 ³ Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo
11 University, Cairo, Egypt

12 *Corresponding author: ael.nagish@science.sohag.edu.eg

13 **Abstract**

14 Linezolid resistance has become a focal point worldwide, particularly as
15 linezolid stands as one of the last resort antibiotics against multiple-drug resistant
16 bacterial strains. Despite its critical importance, the situation in Egypt remains
17 relatively unexplored. As various linezolid resistance mechanisms have been
18 identified in staphylococci, our investigation aims to uncover the molecular
19 characteristics of staphylococci showing reduced susceptibility to Linezolid at Kasr-
20 El-Eini Teaching Hospital. Thirty isolates were investigated in this study. The
21 selected samples, identified by Vitek 2 system and confirmed by 16S rRNA, were
22 examined by disc diffusion method. Of the 30 isolates, two were confirmed as
23 linezolid resistant and screened for the presence of *cfr* gene and mutations in the

24 Domain V of the 23S rRNA gene. Both of the studied strains, identified as
25 *Staphylococcus haemolyticus*, SZ-2 and SZ-7 harbored two point mutations G2576T
26 and G2602T in the Domain V of the 23S rRNA gene. A novel G2694C mutation
27 reported for the first time was detected in strain SZ-7. The presence of *cfr* gene was
28 confirmed in both isolates. Linezolid-resistant *Staphylococcus haemolyticus* had
29 emerged in ICU patients with prior antibiotic exposure. The exact role of the novel
30 G2694C mutation in linezolid resistance needs further investigations. The study
31 underscores the importance of proper surveillance of *cfr*-carrying strains in the
32 healthcare settings in Egypt.

33 **Keywords**

34 Linezolid, Resistance, Domain V, 23S rRNA, Mutations, *Staphylococcus*
35 *haemolyticus*

36 **Introduction**

37 *Staphylococcus haemolyticus*, a coagulase-negative staphylococci (CoNS),
38 naturally resides in the human skin tissue microbiota with the potential to induce
39 various illnesses, such as skin infections, bloodstream infections, and other several
40 nosocomial infections [1]. In recent years, broad-spectrum antibacterials were widely
41 used in clinical settings, that led to a persistent rise in drug resistance. The current
42 surge in bacterial drug resistance is a cause for serious concern [2]. Linezolid, an
43 oxazolidinone antibiotic, was approved for clinical use in 2000 [3]. This antibiotic is
44 potent against multidrug-resistant Gram-positive bacteria, including methicillin-
45 resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE),
46 and *Streptococcus pneumoniae* [4]. Activity of linezolid results from binding to the
47 23S rRNA in the 50S ribosomal subunit. Thus, it acts as an inhibitor of protein

48 synthesis by binding to the ribosomal peptidyl transferase center (PTC) affecting
49 tRNA positioning and eventually stopping the growth of bacteria [5,6].

50 The prevalence of linezolid resistance is steadily on the rise due to the
51 extensive utilization of this antibiotic. Numerous reports have documented cases of
52 linezolid-resistant staphylococci. The most well-established mechanisms underlying
53 the development of linezolid-resistant staphylococci involves a mutation in the 23S
54 rRNA gene target and the acquisition of the chloramphenicol-florfenicol resistance
55 (cfr) gene [7,8,9,10]. The 23S rRNA, a constituent of the bacterial ribosome 50S
56 subunit, can undergo mutations during exposure to linezolid, rendering the drug
57 ineffective and ultimately resulting in drug resistance. Additionally, gene mutation
58 sites exhibit variability among different strains [10, 11]. Among Staphylococcus
59 strains, G2576T gene mutation is the most prevalent [11,12,13,14]. cfr gene, first
60 identified in plasmids of Staphylococcus isolates from German cows, encodes a
61 methyltransferase capable of modifying 23S rRNA [15]. The cfr gene facilitates
62 methylation at specific sites on the ribosomal large subunit, leading to resistance
63 against linezolid [5,16].

64 At our Kasr-El-Eini Teaching Hospital, the escalating concern lies in
65 staphylococcal isolates in the intensive care units, which exhibit an extraordinary
66 predisposition to develop resistance to all available antibiotics including linezolid.
67 Consequently, in pursuit of viable treatment alternatives, there is a pressing need to
68 comprehend the resistance mechanism of such isolates. Henceforth, this study was
69 undertaken to investigate the molecular characteristics of linezolid-resistant S.
70 haemolyticus identified in clinical infections. A collection of linezolid-resistant CoNS
71 (LRCoNS) from 30 patients were evaluated for mechanisms of linezolid resistance.

72 **Materials and Methods**

73 **Sample collection, identification and antimicrobial susceptibility testing of** 74 **bacterial isolates**

75 Over two years; from March 2020 to March 2022, a total of 30 clinical isolates
76 of staphylococci showing reduced susceptibility to Linezolid were collected from
77 Kasr El-Eini Teaching Hospital. Samples were isolated from different specimens,
78 including pus and blood. Disc diffusion method was used to screen isolates for
79 linezolid resistance. Linezolid concentration used was 30 µg. The antimicrobial discs
80 were obtained from Oxoid Ltd (Basingstoke, Hampshire, England, UK) and processed
81 according to the manufacturer's instructions.

82 The identification of isolates was performed using conventional techniques
83 such as cultivation on mannitol salt agar [17] and deoxyribonuclease (DNase) agar
84 [18]. The isolates were further identified using VITEK 2 system (bioMérieux, Marcy-
85 l'Étoile, France) using the VITEK 2 GP Card according to the manufacturer's
86 instructions. The antibiotic susceptibility test of isolates was performed on Mueller
87 Hinton agar using the Kirby Bauer disc diffusion method [19] as per Clinical and
88 Laboratory Standard Institute [20] guidelines using antibiotic Linezolid 30 µg.
89 Subsequently, identification of the selected bacterial isolates was confirmed by 16S
90 rRNA gene [21]. All the relevant clinical data were collected for analysis, including
91 dose and length of linezolid treatments and other results of antimicrobial
92 susceptibility tests.

93 **Mechanisms of linezolid resistance among the isolates**

94 The two most resistant *Staphylococcus haemolyticus* strains (namely SZ-2 and
95 SZ-7) were selected and screened for point mutations in Domain V of the 23S rRNA

96 gene and the presence of the *cfr* gene by PCR and DNA sequencing as described
97 previously [7,8,9,10].

98 The genomic DNA was isolated using Quick-DNA™ Miniprep Kit from
99 Zymo Research™ according to the manufacturer instruction manual. Amplification
100 was performed using the following PCR conditions: 35 cycles of denaturing,
101 annealing, and extension at 94°C (30 s), 55°C (30 s), and 72°C (1 min) respectively;
102 and a final 10-min extension at 72°C.

103 To elucidate the mechanism of linezolid resistance, screening for *cfr* gene and
104 point mutations in domain V of 23S rRNA gene were investigated by amplifying the
105 loci using the PCR conditions described by Yoo et al [8]. Amplification by PCR was
106 performed using primers listed in Table 1. Amplicons were sequenced on both strands
107 and sequences were aligned with the corresponding sequences from linezolid-
108 susceptible *S. haemolyticus* JCSC 1435 (GenBank accession No. AP006716). All
109 sequenced data was uploaded to the NCBI under accession numbers shown in the data
110 availability section.

111 **Table 1.** Primers are used for PCR amplification of targeted genes.

Target genes	Primer name	Sequence (5'-3')	Product size (bp)	Reference
Domain V of the 23S rRNA	23S_rRNA_Fw	5'-GCGGTCGCCTCCTAAAAG-3'	390	[22]
	23S_rRNA_Rv	5'-ATCCCGGTCCTCTCGTACTA-3'		
<i>cfr</i> gene	<i>cfr</i> -Fw	5'-TGAAGTATAAAGCAGGTTGGGAGTCA-3'	746	[23]
	<i>cfr</i> -Rv	5'-ACCATATAATTGACCACAAGCAGC-3'		

112

113 **Results and Discussion**

114 Twenty four of the total 30 isolates were found to be totally susceptible to
115 linezolid. Isolates SZ-2 and SZ-7, showed the highest resistance to linezolid, were
116 selected for further investigations. The two isolates were identified as *Staphylococcus*
117 based on their characteristic growth on blood agar and microscopic observations. The
118 isolates were negative for mannitol fermentation, DNase and coagulase test, thus
119 confirming coagulase negative *Staphylococcus*. The Vitek 2 system identified the
120 isolates correctly (Table 2), with a probability of 99% and confidence level
121 'excellent'. The 16S rRNA gene sequence revealed that the isolates are *S.*
122 *haemolyticus* with 99% similarity with *S. haemolyticus* strain JCSC1435 in BLAST
123 search.

124 Strain SZ-2, with a linezolid inhibition zone diameter (IZD) less than 1 mm
125 (zone diameter breakpoint according to CLSI 2023 ≤ 20 mm), was found to have
126 G2576T and G2602T mutations in the Domain V of 23S rRNA gene (Table 2). A
127 novel G2694C mutation in addition to the same two G2576T and G2602T mutations,
128 both in domain V of the 23S rRNA gene, were identified in *S. haemolyticus* strain SZ-
129 7 with a linezolid IZD less than 1 mm.

130 Previous studies have already reported the G2576T and G2602T substitutions
131 in the Domain V of the 23S rRNA gene of linezolid-resistant *Staphylococcus spp.*
132 [2,7,12,13,14,24]. Although both mutations were first reported in 2007 and in 2021,
133 respectively [2,25], this is the first report of these mutations in *S. haemolyticus*
134 isolated in Egypt. The novel mutation G2694C, whether it plays a role in linezolid
135 resistance is uncertain and needs further confirmation. Nevertheless, this revelation

136 may have the potential to contribute valuable insights into investigating the
137 mechanism of linezolid resistance caused by mutations in the V domain of 23S rRNA
138 gene.

139 *cfr* gene in both isolates was detected and confirmed by sequencing the
140 amplicons on both strands. At Kasr-El-Eini Teaching Hospital, isolations of a *cfr*-
141 carrying clinical *S. haemolyticus* isolates from the ICU units is extremely alerting to
142 us. Our greatest concern is the presence of the *cfr* gene in both isolates, as its minimal
143 fitness cost allows cells to retain it even in the absence of selection pressure from the
144 antibiotic. Typically, the *cfr* gene is situated in an unstable genetic environment,
145 either on the chromosome or on multidrug-resistant plasmids [26]. This precarious
146 positioning would facilitate the easy spread of *cfr* into susceptible populations and
147 other pathogenic bacteria. Moreover, *cfr*-mediated resistance confers resistance to a
148 wide-spectrum of antibiotics not only linezolid and thus poses a significant challenge
149 to therapeutic options.

150 Table (2): Mutations detected in the V domain of 23S rRNA gene of the resistant
151 isolates *S. haemolyticus* strain SZ-2 and SZ-7.

Strain	ICU	Clinical sample	Vitek 2 results		Coagulase test	Mutations of the Domain V of 23S rRNA gene	MIC (µg/mm) Linezolid	Linezolid IZD (CLSI 2023)	cfr gene
			P (%)	C.L					
SZ-2	Yes	Blood	99	E	Negative	G2576T, G2602T	30 µg	< 1 mm	+
SZ-7	Yes	Blood	99	E	Negative	G2576T, G2602T,	30 µg	< 1 mm	+

						G2694C			
--	--	--	--	--	--	--------	--	--	--

152 P = Probability, C.L = Confidence Level, E = Excellent, IZD = Inhibition zone
153 diameter; Mutations in 23S rRNA according to *Staphylococcus* numbering
154 (NR_076257.1)

155 Although linezolid resistance due to mutations in Domain V of the 23S rRNA
156 and presence of *cfr* gene were reported in several staphylococcal species from many
157 countries around the world such as Spain [27], the USA [28], Brazil [29], Mexico [30],
158 Japan [31] and Korea [32], this is the first report of these mutations in *S.*
159 *haemolyticus* isolated in Egypt. This first emergence of LRSH in intensive care units
160 in our hospital during a short period is very worrying, requiring serious measures and
161 proper surveillance in the healthcare settings to prevent the intrahospital
162 dissemination of resistant strains. The novel G2694C mutation in Domain V of the
163 23S rRNA, whether it plays a role in linezolid resistance is uncertain and needs
164 further confirmation. Nevertheless, this revelation may have the potential to
165 contribute valuable insights into investigating the mechanism of linezolid resistance
166 caused by mutations in Domain V of the 23S rRNA. The study emphasizes the need
167 for proper surveillance of *cfr*-carrying strains in the healthcare settings in Egypt.

168 **Data availability**

169 All sequenced data was uploaded to the NCBI under accession numbers PP525131-
170 PP525132 for *cfr* genes and PP506638- PP506639 for 23S ribosomal RNA gene of *S.*
171 *haemolyticus* strain SZ-2 and SZ-7 respectively.

172 **Acknowledgements**

173 Not applicable.

174 **Ethical approval**

175 Ethical approval was granted by the Review Board of the Clinical and Chemical
176 Pathology Department, Faculty of Medicine, Cairo University, Egypt prior to the
177 beginning of the study with a waiver of informed consents.

178 **Disclosure statement**

179 The authors declare that there are no conflicts of interest.

180 **Funding**

181 Not applicable.

182 **ORCID**

183 Abdullah El-nagish: <https://orcid.org/0000-0002-5704-5475>

184 **References**

- 185 [1] Czekaj, T., Ciszewski, M., & Szewczyk, E. M. (2015). *Staphylococcus*
186 *haemolyticus* – An emerging threat in the twilight of the antibiotics age.
187 *Microbiol. (United Kingdom, 161)*, 2061–2068.
- 188 [2] Gostev, V., Leyn, S., Kruglov, A., Likholetova, D., Kalinogorskaya, O., Baykina,
189 M., & Sidorenko, S. (2021). Global expansion of linezolid-resistant coagulase-
190 negative staphylococci. *Frontiers in Microbiology*, *12*, 661798.
- 191 [3] Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H., & Vester, B. (2005). A
192 new mechanism for chloramphenicol, florfenicol and clindamycin resistance:
193 Methylation of 23S ribosomal RNA at A2503. *Molecular microbiology*, *57*(4),
194 1064–1073.
- 195 [4] Giessing, A. M. (2009). Identification of 8-methyladenosine as the modification
196 catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic
197 resistance in bacteria. *RNA*, *15*, 327–336.

- 198 [5] Long, K. S., & Vester, B. (2012). Resistance to linezolid caused by modifications
199 at its binding site on the ribosome. *Antimicrobial Agents and Chemotherapy*,
200 56(2), 603–612.
- 201 [6] Sadowy, E. (2018). *Linezolid resistance genes and genetic elements enhancing*
202 *their dissemination in enterococci and streptococci*. Plasmid.
- 203 [7] Zhou, W., Niu, D., Gao, S., Zhong, Q., Liu, C., Liao, X., & Shen, H. (2023).
204 Prevalence, biofilm formation, and mass spectrometric characterization of
205 linezolid-resistant *Staphylococcus capitis* isolated from a tertiary hospital in
206 China. *Journal of Global Antimicrobial Resistance*, 33, 155–163.
- 207 [8] Yoo, I. Y., Kang, O. K., Shim, H. J., Huh, H. J., & Lee, N. Y. (2020). Linezolid
208 resistance in methicillin-resistant *Staphylococcus aureus* in Korea: High rate
209 of false resistance to linezolid by the VITEK 2 system. *Annals of Laboratory*
210 *Medicine*, 40(1), 57–62.
- 211 [9] Han, X., Zou, G., Liu, J., Yang, C., Du, X., Chen, G., & Jiang, X. (2022).
212 Mechanisms of linezolid resistance in *Staphylococcus capitis* with the novel
213 mutation C2128T in the 23S rRNA gene in China. *BMC Microbiology*, 22(1),
214 203.
- 215 [10] Maarouf, L., Omar, H., El-Nakeeb, M., & Abouelfetouh, A. (2021). Prevalence
216 and mechanisms of linezolid resistance among staphylococcal clinical isolates
217 from Egypt. *European Journal of Clinical Microbiology & Infectious*
218 *Diseases*, 40, 815–823.
- 219 [11] Almeida, L. M., Lincopan, N., Araújo, M. R. E., & Mamizuka, E. M. (2012).
220 Clonal dissemination of linezolid-resistant *Staphylococcus haemolyticus*
221 exhibiting the G2576T mutation in the 23S rRNA gene in a tertiary care
222 hospital in Brazil. *Antimicrobial Agents and Chemotherapy*, 56(5), 2792.

- 223 [12] Balandin, B., Lobo, B., Orden, B., Román, F., García, E., Martínez, R., ... &
224 Galdos, P. (2016). Emergence of linezolid-resistant coagulase-negative
225 staphylococci in an intensive care unit. *Infectious Diseases*, 48(5), 343-349.
- 226 [13] Hegstad, K., Longva, J. Å., Hide, R., Aasnæs, B., Lunde, T. M., & Simonsen, G.
227 S. (2014). Cluster of linezolid-resistant *Enterococcus faecium* ST117 in
228 Norwegian hospitals. *Scandinavian journal of infectious diseases*, 46(10),
229 712-715.
- 230 [14] Mazzariol, A., Kocsis, E., Bragagnolo, L., Pellizzer, G., Rattu, M., & Cornaglia,
231 G. (2012). Co-infection by two linezolid-resistant coagulase-negative
232 staphylococci with two different resistance determinants. *Scandinavian*
233 *journal of infectious diseases*, 44(12), 978-981.
- 234 [15] Toh, S.-M. (2007). Acquisition of a natural resistance gene renders a clinical
235 strain of methicillin-resistant *Staphylococcus aureus* resistant to the synthetic
236 antibiotic linezolid. *Mol. Microbiol*, 64, 1506–1514.
- 237 [16] LaMarre, J. M., Locke, J. B., Shaw, K. J., & Mankin, A. S. (2011). Low fitness
238 cost of the multidrug resistance gene *cfr*. *Antimicrob. Agents Chemother*, 55,
239 3714–3719.
- 240 [17] Kateete, D. P., Kimani, C. N., Katabazi, F. A., Okeng, A., Okee, M. S., &
241 Nanteza, A. (2010). Identification of *Staphylococcus aureus*: DNase and
242 Mannitol salt agar improve the efficiency of the tube coagulase test, *Ann.*
243 *Clin. Microb. Antimicrob*, 9, 23.
- 244 [18] Boerlin, P., Kuhnert, P., Hussy, D., & Schaellibaum, M. (2003). Methods for
245 identification of *Staphylococcus aureus* isolates in cases of bovine mastitis. *J*
246 *Clin Microbiol*, 41, 767–771.
- 247 [19] Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol.

- 248 *American society for microbiology, 15, 55–63.*
- 249 [20] CLSI, M. (2023). *Performance Standards for Antimicrobial Susceptibility*
250 *Testing* (33rd ed.).
- 251 [21] White, T. J., Bruns, T., Lee, S. J. W. T., & Taylor, J. (1990). Amplification and
252 direct sequencing of fungal ribosomal RNA genes for phylogenetics. *PCR*
253 *Protocols: A Guide to Methods and Applications, 18, 315–322.*
- 254 [22] Meka, V. G., Pillai, S. K., Sakoulas, G., Wennersten, C., Venkataraman, L., &
255 DeGirolami, P. C. (2004). Linezolid resistance in sequential *Staphylococcus*
256 *aureus* isolates associated with a T2500A mutation in the 23S rRNA gene and
257 loss of a single copy of rRNA. *J Infect Dis, 190, 311–317.*
- 258 [23] Lee, S. M., Huh, H. J., Song, D. J., Shim, H. J., Park, K. S., & Kang, C. I. (2017).
259 Resistance mechanisms of linezolid-nonsusceptible enterococci in Korea: Low
260 rate of 23S rRNA mutations in *Enterococcus faecium*. *J Med Microbiol, 66,*
261 *1730–1735.*
- 262 [24] Almeida, L. M., Araújo, M. R. E., Sacramento, A. G., Pavez, M., Souza, A. G.,
263 Rodrigues, F., & Mamizuka, E. M. (2013). Linezolid resistance in Brazilian
264 *Staphylococcus hominis* strains is associated with L3 and 23S rRNA
265 ribosomal mutations. *Antimicrobial Agents and Chemotherapy, 57(8), 4082.*
- 266 [25] Tarazona, R. E. R., Padilla, T. P., Gómez, J. C. S., Sánchez, J. E. G., &
267 Hernandez, M. S. (2007). First report in Spain of linezolid non-susceptibility
268 in a clinical isolate of *Staphylococcus haemolyticus*. *International Journal of*
269 *Antimicrobial Agents, 3(30), 277–278.*
- 270 [26] Gopegui, E. R., Juan, C., Zamorano, L., Perez, J. L., & Oliver, A. (2012).
271 Transferable multidrug resistance plasmid carrying cfr associated with tet(L),
272 ant (4')-Ia, and dfrK genes from a clinical methicillin resistant *Staphylococcus*

- 273 aureus ST125 strain. *Antimicrob Agents Chemother*, *56*, 2139–2142.
- 274 [27] Morales Kucharski, M. G., Picazo, J. J., Baos, E., Candel, F. J., Arribi, A., Peláez
275 Ros, B., & Sánchez García, M. (2010). *Resistance to linezolid is mediated by*
276 *the cfr gene in the first report of an outbreak of linezolid-resistant*
277 *Staphylococcus aureus*.
- 278 [28] Bonilla, H., Huband, M. D., Seidel, J., Schmidt, H., Lescoe, M., McCurdy, S. P.,
279 & Quinn, J. P. (2010). Multicity outbreak of linezolid-resistant
280 *Staphylococcus epidermidis* associated with clonal spread of a cfr-containing
281 strain. *Clinical Infectious Diseases*, *51*, 796–800.
- 282 [29] Gales, A. C., Sader, H. S., Andrade, S. S., Lutz, L., Machado, A., & Barth, A. L.
283 (2006). Emergence of linezolid-resistant *Staphylococcus aureus* during
284 treatment of pulmonary infection in a patient with cystic fibrosis. *International*
285 *Journal of Antimicrobial Agents*, *27*, 300–302.
- 286 [30] Mendes, R. E., Deshpande, L., Rodriguez-Noriega, E., Ross, J. E., Jones, R. N.,
287 & Morfin-Otero, R. (2010). First report of staphylococcal clinical isolates in
288 Mexico with linezolid resistance caused by cfr: Evidence of in vivo cfr
289 mobilization. *Journal of Clinical Microbiology*, *48*, 3041–3043.
- 290 [31] Ikeda-Dantsuji, Y., Hanaki, H., Sakai, F., Tomono, K., Takesue, Y., Honda, J.,
291 Nonomiya, Y., Suwabe, A., Nagura, O., & authors. (2011). Linezolid-resistant
292 *Staphylococcus aureus* isolated from 2006 through 2008 at six hospitals in
293 Japan. *J Infect Chemother*, *17*, 45–51.
- 294 [32] An, D., Lee, M. Y., Jeong, T. D., Sung, H., Kim, M. N., & Hong, S. B. (2011).
295 Co-emergence of linezolid-resistant *Staphylococcus aureus* and *Enterococcus*
296 *faecium* in a patient with methicillin-resistant *S. aureus* pneumonic sepsis.
297 *Diagnostic Microbiology and Infectious Disease*, *69*, 232–233.

It is made available under a [CC-BY 4.0 International license](#) .

298

299

300